Parameters proposed to be related to the metabolite intestinal concentrations and the parameter distributions used to model variability in possible concentrations of antimicrobially active ceftiofur metabolites in the small and large intestines of cattle treated with ceftiofur parenterallyParameter DefinitionDistributionData used to derive distributionCEbioCEabioRate of ceftiofur metabolites biotic degradation in small and large intestines per hour possible dependency of b-lactamase production by enteric bacteria on the CE concentration was not included Rate of metabolites abiotic degradation in GI tract through hydrolysisUniform 015 025 --Antimicrobial activity of main product is close to parent drugCEFraction of metabolites excreted in bileUniform 024 045 CErest siCEliCEupper siCErest siCEliFraction of metabolites adsorbed to the digesta in the lower 23 of small intestineFraction of metabolites adsorbed to the digesta in large intestineFractional digesta flow through the upper 13 of small intestine per hourFractional digesta flow through the lower 23 of small intestine per hourFractional digesta flow through large intestine per hour to defecationNot included in model simulationsNot included in model simulations032370161903030Vrest siVolume of digesta in the lower 23 of small intestine litreUniform 4 23VliVolume of digesta in large intestine litreUniform 6 22Deterministic estimates of the dynamics of ceftiofur metabolites in the central circulation published by the drug manufacturer were used in all simulations.

Parameters associated with the maximum concentrations of antimicrobially active ceftiofur metabolites in the lower 23 of small intestines of beef cattle administered ceftiofur parenterallyParameterDefinitionDistributionFractional contribution to the variance of maximum CE concentrationsr between the variable value and maximum CE concentration given variability due to all othervariables related to CE intestinal fateCEbioRate of ceftiofur metabolites biotic degradation in small and large intestines per hourUniform 015 0257-031 P-value 4 001CEFraction of metabolites excreted in bileUniform 024 0458032 P-value 4 001Vrest siVolume of digesta in the lower 23 of small intestine litreUniform 4 2362-085 P-value 4 001The model was simulated 1000 times assuming the metabolites passed through intestine with liquid digesta phase.

Parameters associated with the maximum concentrations of antimicrobially-active ceftiofur metabolites in the large intestines of beef cattle administered ceftiofur parenterallyParameterDefinitionDistributionFractional contribution to the variance of maximum CE concentrationsr between the variable value and maximum CE concentration given variability due to all other variables related to CE intestinal fateCEbioRate of ceftiofur metabolites biotic degradation in small and large intestines per hourUniform 015 02523-050 P-value 4 001CEFraction of metabolites excreted in bileUniform 024 04514041 P-value 4 001VliVolume of digesta in large intestine litreUniform 6 2253-076 P-value 4 001The model was simulated 1000 times assuming the metabolites passed through intestine with liquid digesta phase.

The correspondence between the pre- dictions and data has improved with this ceftiofur model formulation incorporating the metabolite biotic degradation in small intestine and updated estimates of the digesta contents volumes the earlier deterministic model formulation predicted lower CE concentrations in large intestine .Distributions of variables related to intestinal fate of ceftiofur metabolitesDistributions assigned to the variables related to the CE intestinal concentrations are summarized in .

Parameters proposed to be related to the drug intestinal concentrations and the parameter distributions used to model variability in possible concentrations of CTC in the small and large intestines of beef cattle during the 5-day per os treatmentParameterDefinitionDistributionData used to derive distributionCTCabioRate of CTC abiotic degradation in GI tract and other body parts per hourBeta 054 374   -CTCbFraction of CTC excreted in bileUniform 039 064-25 estimate CTCrest silirest silisFraction of CTC adsorbed to the digesta in the lower 23 of small intestinelower 23 of small intestinea intestineaUniform 069 089-upper sirest siliThe animals ingested CTC in equal portions during each 12 h of day time per day of the 5-day therapy.

We simulated the influence of variation in the variables related to the CE intestinal fate above and  on the outcome - the CE concentrations undegraded and assumed to remain unsorbed antimicrobially active ceftiofur metabolites in the small and large intestines during the treatment and the intestinal elimination period.Concentration of antimicrobial drugs in intestine2087Simulation and analysis of the modelsEach model was simulated 1000 times in Vensimr Professional software Ventana Systems Inc Harvard MA USA with Latin Hypercube Sampling  of the value of each variable related to the drugmetabolite intestinal fate from the assumed distribution except for the digesta transit rates that were explicitly defined for the two diet scenarios for the CTC model.

Parameters associated with the maximum concentrations of CTC in the lower 23 of small intestines of beef cattle during the 5-day per os treatmentParameterDefinitionDistributionFractional contribution to the variance of maximum CTC concentrationsr between the variable value and maximum CTC concentration given variability due to all other variables related to CTC intestinal fateCTCabioCTCRate of CTC abiotic degradation in GI tract and other body parts per hourBeta 054 374A 7 B 9A -030 P-value 4 001 B -034 P-value 4 001EbFraction of CTC excreted in bileUniform 039 064A 008 B 038A 002 P-value  0566 B 004 P-value  0159CTCrest siFraction of CTC adsorbed to the digesta or microbiome in the lower 23 of small intestineUniform 069 089A 21B 14A -054 P-value 4 001 B -043 P-value 4 001VrestsiVolume of digesta in the lower 23 of small intestine litreUniform 4 23A 54B 50A -078 P-value 4 001 B -077 P-value 4 001The model was simulated 1000 times assuming the animals consumed A - grain-based diet or B - long-form hay-based diet.

Parameters associated with the maximum concentrations of CTC in the large intestines of beef cattle during the 5-day per os treatmentParameterDefinitionDistributionFractional contribution to the variance of maximum CTC concentrationsr between the variable value and maximum CTC concentration given variability due to all other variables related to CTC intestinal fateCTCabioCTCRate of CTC abiotic degradation in GI tract and other body parts per hourBeta 054 374A 15 B 18A -042 P-value 4 001 B -047 P-value 4 001EbFraction of CTC excreted in bileUniform 039 064A 0 B 0A 0 P-value  0972B 0 P-value  0576CTCliFraction of CTC adsorbed to the digesta or microbiome in large intestineUniform 069 089A 25B 23A -054 P-value 4 001 B -053 P-value 4 001VliVolume of digesta in large intestine litreUniform 6 22A 44B 43A -067 P-value 4 001 B -065 P-value 4 001The model was simulated 1000 times assuming the animals consumed A - grain-based diet or B - long-form hay-based diet.

.a A single variable - fraction of CTC adsorbed to the digesta or microbiome - was included in the simulations.b Intestinal transit time of CTC was set as the average of the liquid and solid digesta phases.c Forage scenarios were diets A - grain based and B - long-form hay based.on the outcome - the concentrations of antimicrobially active CTC undegraded and unsorbed in the small and large intestines during the treatment and the intes- tinal elimination period.Example 2 cephalosporin ceftiofur by injectionModel structureFrom the framework outlined in  we chose the applicable processes and variables for modeling intestinal concentrations of ceftiofur metabolites .

Those include the drug's fraction inclusive of any active metabolites excreted in bile the drug's fractions and intestinal segments of excretion via other mechanisms the rates and intestinal segments of the drug's absorption and re-absorption the rates and intestinal segments of the drug's abiotic and biotic degradation in the intestine the digesta passage time through the intestinal segments the rates mechanisms and reversibility of the drug's sorption to the digesta and enteric microbiome and the volume of luminal contents in the intestinal segments.

